Handelsbanken Fonder AB Sells 3,100 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Handelsbanken Fonder AB lessened its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Rating) by 34.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 5,800 shares of the biopharmaceutical company’s stock after selling 3,100 shares during the quarter. Handelsbanken Fonder AB’s holdings in Celldex Therapeutics were worth $259,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of CLDX. Silverarc Capital Management LLC increased its position in shares of Celldex Therapeutics by 0.9% during the 1st quarter. Silverarc Capital Management LLC now owns 45,538 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 406 shares during the last quarter. First Trust Advisors LP boosted its stake in Celldex Therapeutics by 4.4% in the 3rd quarter. First Trust Advisors LP now owns 10,399 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 440 shares during the period. Point72 Hong Kong Ltd boosted its stake in Celldex Therapeutics by 57.9% in the 1st quarter. Point72 Hong Kong Ltd now owns 1,394 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 511 shares during the period. Nisa Investment Advisors LLC boosted its stake in Celldex Therapeutics by 109.0% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,024 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 534 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its stake in Celldex Therapeutics by 2.7% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 30,242 shares of the biopharmaceutical company’s stock valued at $850,000 after purchasing an additional 803 shares during the period.

Celldex Therapeutics Stock Up 5.7 %

Shares of CLDX stock opened at $33.28 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 17.07 and a current ratio of 17.07. Celldex Therapeutics, Inc. has a twelve month low of $19.85 and a twelve month high of $48.40. The business has a fifty day simple moving average of $37.04 and a 200 day simple moving average of $39.23.

Celldex Therapeutics (NASDAQ:CLDX – Get Rating) last posted its earnings results on Tuesday, February 28th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.03. The firm had revenue of $1.61 million during the quarter, compared to the consensus estimate of $0.16 million. Celldex Therapeutics had a negative return on equity of 31.82% and a negative net margin of 3,766.22%. On average, research analysts predict that Celldex Therapeutics, Inc. will post -2.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. StockNews.com assumed coverage on Celldex Therapeutics in a research report on Thursday, March 16th. They set a “sell” rating for the company. HC Wainwright reiterated a “buy” rating and set a $73.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, March 1st. Finally, Cantor Fitzgerald cut their target price on Celldex Therapeutics from $55.00 to $54.00 in a research report on Friday.

About Celldex Therapeutics

(Get Rating)

Celldex Therapeutics, Inc engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.